Millie
your market intelligence analyst
Search Results
502 results
Your search is now limited to «Novartis» expert search.
Medical Marketing & Media 07/19/2019 13:22
Novartis has frequently denied the accusations, which stem from a whistleblower suit filed in 2011 by a former employee, later joined by the federal government.
More from Medical Marketing & Media:
Business Insider 07/19/2019 12:11
When Vas Narasimhan started as the new CEO of Swiss drug giant Novartis, he began refocusing the company on a key business area: prescription medicines.
More from Business Insider:
FierceMedicalDevices 07/19/2019 09:40
The West Coast Big Biotech, which has been shuffling its execs over the past few weeks, today licensed three preclinical antiviral programs from Novartis including investigational agents with the potential to treat human rhinovirus, influenza and herpes.
More from FierceMedicalDevices:
FiercePharmaManufacturing 07/19/2019 09:28
Novartis’ sunny Sandoz forecast is at odds with the reality of the US generics market: analysts.
More from FiercePharmaManufacturing:
ENDPOINTS 07/19/2019 09:09
The big biotech today snapped up 3 preclinical antiviral programs from pharma giant Novartis, with drugs promising to treat human rhinovirus, influenza and herpes viruses.
More from ENDPOINTS:
Business Wire 07/19/2019 08:30
Novartis will receive an upfront payment and is eligible to receive up to an additional $291 million in potential milestone payments upon achievement of certain development and commercial milestones, as well as royalties on annual net ...
More from Business Wire:
PharmiWeb.com 07/19/2019 07:05
Novartis is committed to bringing innovation to China and to reimagining care for patients.
More from PharmiWeb.com:
Pharmafile 07/19/2019 06:09
Novartis has revealed that its disease modifying drug Gilenya (fingolimod) has secured approval in China for the treatment of relapsing forms of multiple sclerosis (RMS), almost a decade after it originally received marketing authorisation in the ...
More from Pharmafile:
PMLiVE 07/19/2019 05:41
Medicxi III was amassed in just six weeks, much quicker than usual, with Novartis and Johnson & Johnson Innovation among the key investors along with “established hospital foundations and medical institutions.
More from PMLiVE:
ETHealthWorld (India) 07/19/2019 03:01
Nearly a decade after its U.S. approval, Gilenya remains Novartis's No. 2 revenue generator at $825 million in the second quarter.
More from ETHealthWorld (India):
Channel NewsAsia (Singapore) 07/19/2019 02:15
World Novartis's Gilenya multiple sclerosis drug has won approval in China, the Swiss drugmaker said on Friday, as the company expands further into the world's most-populous country's growing healthcare sector.
More from Channel NewsAsia (Singapore):
Seeking Alpha 07/18/2019 16:57
Second, on Zolgensma, historically, Novartis has provided guidance for full year for the newly launched products, I’m thinking of Entresto and Cosentyx.
More from Seeking Alpha:
BioPharma Dive 07/18/2019 15:28
With the agreement, Novartis gains dedicated space at a new facility near the Baltimore-Washington International Airport built by Paragon Gene Therapy, a Catalent unit acquired in an April deal.
More from BioPharma Dive:
Motley Fool 07/18/2019 15:09
Second, on Zolgensma, historically, Novartis has provided guidance for full year for the newly launched products -- I'm thinking of Entresto and Cosentyx.
More from Motley Fool:
FDLI SmartBrief 07/18/2019 11:52
The UK's National Institute of Health and Care Excellence has recommended the use of Novartis' Kisqali, or ribociclib, combined with fulvestrant to treat patients with advanced breast cancer as an alternative to the regimen consisting of exemestane plus everolimus.
More from FDLI SmartBrief:
BioPharma-Reporter 07/18/2019 10:22
Through the long-term agreement, the gene therapy treatment from AveXis, which was acquired by Novartis in April 2018 for $8.7bn (€7.75bn), will have dedicated production space at a commercial manufacturing center in Baltimore, Maryland, established by Paragon Gene Therapy.
More from BioPharma-Reporter:

Therapeutic Areas

Clinical Trials and Phases

Business Issues

Companies - Public

Companies - Venture Funded

Financial Results

Global Markets

Global Risk Factors

Government Agencies

Job Titles

Legal and Regulatory

Cell Receptors

Cells

Diagnostics and Therapeutics

Diseases

Drugs - Brand Names

Drugs - Generic

Enzymes

Genes

Health Care

Health and Wellness

Human Anatomy

Mechanisms of Action

Medical Devices

Proteins

Sources

Strategic Scenarios

Trends

Hints:

On this page, you see the results of the search you have run.  You may also view the following:

  •  Click on this drop-down menu on the right hand side of the page, to choose between the machine learning-produced Insights Reports, or the listing of concepts extracted from the results, in chart or list format. 


  •  View the number of search results returned for the search in each of your collections, and click on any of those numbers to view the entire listing of results from the chosen collection.

  •  Use the search adjustment drop-downs to change the scope, sorting, and presentation of your results.

  •  Show or hide the record’s caption (content description).

  •  Show actions that can be made with the search result record.

  •  Click on the Save button after running your search, to save it so that its results will be updated each time relevant new content is added to the designated collection. You may choose to be notified via search alerts.

Click here for more info on Search Results

Click here for more info on Machine Learning applications